Session » Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

Date: Saturday, November 6, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0147

A Qualitative Analysis of Methotrexate Self-Injection Education Videos on YouTube: An Update

8:30AM-10:30AM: Abstract Number: 0137

Antiviral Use and Healthcare Resource Utilization Among Patients with Rheumatoid Arthritis and Influenza in Three Influenza Seasons, 2016–2019

8:30AM-10:30AM: Abstract Number: 0131

Association of Numeracy with Medication Non-Adherence in Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0133

Cervical Cancer Screening Rate in Women with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0130

Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients: Real World Observation Across Disease Severity and Payer Channels in the U.S

8:30AM-10:30AM: Abstract Number: 0135

Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression

8:30AM-10:30AM: Abstract Number: 0142

Description of a Scleroderma Cohort and Management of Lung Disease Risk at a Rural Academic Medical Center

8:30AM-10:30AM: Abstract Number: 0143

Economic and Healthcare Resource Use Burden of Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 0144

Healthcare Utilization and Costs Following Kawasaki Disease in Ontario, Canada

8:30AM-10:30AM: Abstract Number: 0132

Hospitalization Rates Among Patients with Systemic Lupus Erythematosus: A Population Based Study

8:30AM-10:30AM: Abstract Number: 0148

Implementation of an Interprofessional Safety Check to Screen for Latent Tuberculosis at an Academic Tertiary Referral Rheumatology Clinic Increased Screening Rates Compared to Historical Levels

8:30AM-10:30AM: Abstract Number: 0146

Improving Medication Toxicity Lab Monitoring During the COVID-19 Pandemic

8:30AM-10:30AM: Abstract Number: 0128

Increased Risk of Major Adverse Cardiac Events in Patients with Systemic Lupus Erythematosus After Non-Cardiac Surgery

8:30AM-10:30AM: Abstract Number: 0129

Real-World Flare Rates and Progression by Treatment Settings Among the Commercially-Insured Systemic Lupus Erythematosus Population in the U.S

8:30AM-10:30AM: Abstract Number: 0145

Rheumatology Provider Perspectives on Using Patient-Reported Outcomes in Clinical Care

8:30AM-10:30AM: Abstract Number: 0134

Systemic Lupus Erythematosus Is a Risk Factor for Mortality in Older Patients with Early-Stage Breast Cancer

8:30AM-10:30AM: Abstract Number: 0140

Therapeutic Management and Clinical Remission in a Specialized Dermatological-Rheumatological Center for Patients with Psoriasis and Psoriatic Arthritis

8:30AM-10:30AM: Abstract Number: 0139

Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists in an Academic Health System: A Retrospective Study

8:30AM-10:30AM: Abstract Number: 0138

Treatment with Adalimumab in Patients with Chronic Inflammatory Rheumatic Diseases: A Study of Treatment Trajectories on a Patient Level in Clinical Practice

8:30AM-10:30AM: Abstract Number: 0136

Underutilization of Mental Health Services in a Busy Tertiary Care Rheumatology Facility

8:30AM-10:30AM: Abstract Number: 0141

Who Gets Influenza Vaccinations Prior to and After a Diagnosis of RA? Results from the Canadian Early Arthritis Cohort (CATCH)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].